ReviewCancer management and research2026
VEGF-Leptin Crosstalk in Breast and Ovarian Cancer: Drivers of Angiogenesis and Progression.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast and ovarian cancers (BC and OC) remain among the leading causes of cancer-related deaths among women worldwide. Their progression is critically dependent on tumor angiogenesis and a permissive metabolic microenvironment. Vascular endothelial growth factor (VEGF) is a key factor in tumor angiogenesis and neovascularization. Leptin, conversely, a hormone that is produced by adipocytes, serves as an important mediator of tumor proliferation, inflammation, and metastasis. Increasing evidence suggests that VEGF and leptin act via multiple overlapping oncogenic pathways. They collectively promote tumor growth, survival, and angiogenesis. Obesity, hypoxia, and interactions between adipose tissue and the stroma further enhance this oncogenic axis by increasing the expression of VEGF and leptin and supporting metabolic reprogramming of the tumor. In BC and OC, persistent activation of the VEGF-leptin network contributes to aggressive disease progression, treatment resistance, and unfavorable clinical outcomes. Studies have indicated cytokine release, hypoxia and necrosis induction, angiogenesis, and tumor metastasis by interconnected immune pathways mediated by leptin and VEGF. Important roles of different receptors have also been uncovered in several in-vitro and in-vivo experiments. The findings have opened avenues for developing targeted monotherapies and combination therapeutic strategies to control tumor progression by inhibiting diverse signaling pathways. This review highlights the reciprocal VEGF-leptin feedback interaction in obesity-associated BC and OC, integrating evidence form biomarker studies and therapeutic perspectives. It also examines the influence of obesity and hypoxia on tumor progression and discusses current therapeutic strategies targeting this interconnected angiogenic-metabolic interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.